APOE and Alzheimer disease: Bexarotene and its derivatives may lower Aβ concentrations in transgenic mouse models of AD via ABCA1- and ABCG1-mediated increase in apoE lipidation, although increased microglial phagocytosis and enzymatic degradation of Aβ has also been detected (Yuan et al., 2019).